Please assess the completion status of the following clinical trial:

Trial Title: Simethicone and N-acetylcysteine in Upper Endoscopy - Prospective Double-blinded Randomized Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* consecutive series of patients scheduled for upper gastrointestinal endoscopy~* signed informed consent~Exclusion Criteria:~* sedation~* previous total gastrectomy~* known neoplasia or stenosis~* therapeutic or urgent procedures~* allergies to simethicone or N-acetylcysteine

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Group A - 100mL of water by mouth, 15 to 30 minutes before endoscopy
- Simethicone (Type: ACTIVE_COMPARATOR): Group B - 100mL of water plus 100mg Simethicone by mouth, 15 to 30 minutes before endoscopy
- Simethicone plus N-acetylcysteine (Type: ACTIVE_COMPARATOR): Group C - 100mL of water plus 100mg Simethicone plus 600mg N-acetylcysteine by mouth, 15 to 30 minutes before endoscopy

Based on this trial design, predict the completion outcome and termination type (if applicable).